Notes

Inflamed Biomarkers throughout Febrile Seizure: A thorough Bibliometric, Review as well as Visual images Examination.
. Rheumatologists should be aware of these comorbidities, especially in the era of COVID-19 pandemic.Irritable bowel syndrome (IBS) is the commonest cause of recurrent abdominal pain in children in both more developed and developing parts of the world. It is characterized by abdominal pain that is improved by defecation and whose onset is associated with a change in stool form and/or frequency and is not explained by structural or biochemical abnormalities. A number of potential patho-physiological mechanisms have been described, but so far the exact underlying etiology of IBS is unclear. Likewise, no optimal treatment has ever been found neither for adult nor for pediatric patients. Current therapeutic options include drugs, dietary interventions and biopsychosocial therapies. The present review aims at evaluating the scientific evidence supporting the efficacy of these treatments for children with IBS.The advent of new genome-wide sequencing technologies has uncovered abnormal RNA modifications and RNA editing in a variety of human cancers. The discovery of reversible RNA N6-methyladenosine (RNA m6A) by fat mass and obesity-associated protein (FTO) demethylase has led to exponential publications on the pathophysiological functions of m6A and its corresponding RNA modifying proteins (RMPs) in the past decade. Some excellent reviews have summarized the recent progress in this field [1-11]. Compared to the extent of research into RNA m6A and DNA 5-methylcytosine (DNA m5C) [12], much less is known about other RNA modifications and their associated RMPs, such as the role of RNA m5C and its RNA cytosine methyltransferases (RCMTs) in cancer therapy and drug resistance [13-17]. see more In this review, we will summarize the recent progress surrounding the function, intramolecular distribution and subcellular localization of several major RNA modifications, including 5' cap N7-methylguanosine (m7G) and 2'-O-methylation (Nm), m6A, m5C, A-to-I editing, and the associated RMPs. We will then discuss dysregulation of those RNA modifications and RMPs in cancer and their role in cancer therapy and drug resistance.Cardiovascular Diseases (CVD) remain the leading cause of mortality and morbidity worldwide. To date, significant progress has been made in developing stimuli-responsive nanosystems that can intrinsically interact with pathological microenvironment to achieve site-specific delivery along with on-demand drug release for precise CVD treatment. Herein, this review summarizes recent advances on smart nanosystems in response to a wide range of biological cues, including pH, enzymes, ROS, shear force, ATP, etc., which can boost drug delivery performance or monitor disease progression in a non-invasive manner. The designs, compositions and main outcomes of the single and multi- responsive nanosystems for drug delivery and/or detection purposes are provided and discussed.
Prussian Blue (PB) is available as conventional release dosage form "Radiogardase" with effective daily dose 3-10 g (very high). The target site is duodenum where it inhibits enterohepatic circulation of Cs & Tl ions, enhancing their fecal excretion.

To enhance efficacy, target release, reduce dose and side effects, oral pH dependent matrix formulation of PB based on in-situ gelation of sodium alginate along with calcium salts was formulated and evaluated.

Different combinations of matrix granules were formulated and optimized. The optimized one was compressed using Polyvinylpyrrolidone K30 (Pvp K30) in different batches and optimized. Langmuir adsorption isotherm was used to assess in-vitro binding efficacy of formulation to thallium using atomic absorption spectroscopy. The proof of concept i.e. drug release in duodenum was studied through pharmacoscintigraphy using radiolabeled formulation in rabbits.

The optimized granules showed no drug release in acidic medium for 2 h whereas complete empty of basket in basic medium within 30-60 minutes. The matrix tablet formulation with Pvp K30 (10% w/w) was optimized with desired hardness and optimum in-vitro release profile. The release data fitted to various linear kinetic models, Hixson-Crowell r2 (0.9906) best fit, confirmed the erosion based release mechanism. The maximum binding capacity (MBC) was found significantly higher (89.60 mg Tl/g formulation) than that of PB API (65.90 mg Tl /g PB API). Pharmacoscintigraphic images confirmed intact formulation in stomach up to 2h and burst release in intestine thereafter.

The results exemplify oral pH dependent PB matrix formulation which achieved desirable target release at duodenum and in-vitro binding efficacy towards Tl ion was appreciable.
The results exemplify oral pH dependent PB matrix formulation which achieved desirable target release at duodenum and in-vitro binding efficacy towards Tl ion was appreciable.Systemic chemotherapy and radiotherapy have been widely used in clinics for several decades, but their disadvantages, such as systemic cytotoxicity and severe side effects, are the biggest obstacle to maximum therapeutic efficacy. In recent years, the impact of extracellular matrix components in tumor progression has aroused the attention of researchers, and with the rapid development of nanomaterials, extracellular matrix targeted nanomaterials have become a promising strategy in tumor theranostics. In this review, we are going to outline the recent and relevant examples of various tumor extracellular matrix targeted nanomaterials applied in tumor therapy and imaging. And we will discuss the challenges and prospects of nanomaterials for future tumor therapy.
Curcumin is claimed as a potent protectant against gastric ulcer (GU) induced by strong necrotizing agents including NSAIDs through its antioxidant, anti-inflammatory and gastroprotective activities. However, it was found to exert opposite effects to either delay ulcer healing or exacerbate ulcer inflammation through some curative mechanisms differently modified by curcumin dosage. Its ability in inhibiting the expression of COX-2 may also delay the healing of NSAIDs-induced GU. Recently, a topical chitosan-curcumin solution has been found to be a safe and potential alternative agent in treating oral ulcer. Therefore, an oral chitosan-curcumin mixture was developed and determined for its efficacy in treating NSAIDs-induced GU in rat.

A chitosan (150 mg)-curcumin (20 mg) mixture with optimal gastric pH was developed. Indomethacin (30 mg/kg) was given orally to the rat and test preparations were administered orally at 5 h later and then every 24 h for two consecutive days. The sum of all gastric ulcerated areas (mm2) for each stomach was used as ulcer index.
My Website: https://www.selleckchem.com/products/tbopp.html